Recent Developments In Bronchial Thermoplasty For Severe Asthma

This article was published in the following Dove Press journal:
Journal of Asthma and Allergy

Neil C Thomson
Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK

Purpose: Bronchial thermoplasty is approved in many countries worldwide as a non-pharmacological treatment for severe asthma. This review summarizes recent publications on the selection of patients with severe asthma for bronchial thermoplasty, predictors of a beneficial response and developments in the procedure and discusses specific issues about bronchial thermoplasty including effectiveness in clinical practice, mechanism of action, cost-effectiveness, and place in management.

Results: Bronchial thermoplasty is a treatment option for patients with severe asthma after assessment and management of causes of difficult-to-control asthma, such as nonadherence, poor inhaler technique, comorbidities, under treatment, and other behavioral factors. Patients treated with bronchial thermoplasty in clinical practice have worse baseline characteristics and comparable clinical outcomes to clinical trial data. Bronchial thermoplasty causes a reduction in airway smooth muscle mass although it is uncertain whether this effect explains its efficacy since other mechanisms of action may be relevant, such as alterations in airway epithelial, gland, and/or nerve function; improvements in small airway function; or a placebo effect. The cost-effectiveness of bronchial thermoplasty is greater in countries where the costs of hospitalization and emergency department are high. The place of bronchial thermoplasty in the management of severe asthma is not certain, although some experts propose that bronchial thermoplasty should be considered for patients with severe asthma associated with non-type 2 inflammation or who fail to respond favorably to biologic therapies targeting type 2 inflammation.

Conclusion: Bronchial thermoplasty is a modestly effective treatment for severe asthma after assessment and management of causes of difficult-to-control asthma. Asthma morbidity increases during and shortly after treatment. Follow-up studies provide reassurance on the long-term safety of the procedure. Uncertainties remain about predictors of response, mechanism(s) of action, and place in management of severe asthma.

Keywords: bronchial thermoplasty, severe asthma

Introduction

Difficult-to-control asthma is an umbrella term used to describe people with poorly controlled asthma due to range of aggravating factors, such as nonadherence, poor inhaler technique, comorbidities, under treatment, and other behavioral factors. A subgroup of patients with difficult-to-control asthma have severe refractory disease despite attempts to identify and manage these aggravating factors and who remain symptomatic despite treatment with high-dose inhaled corticosteroids and long-acting β2-agonist. Severe refractory asthma is uncommon, with prevalence rates estimated to be 3–5% of the total population of adults with asthma.1,2 These
patients are at increased risk of death from asthma and experience considerable morbidity due to poorly controlled disease and the adverse effects of high-dose corticosteroids. The economic burden of severe asthma is high due to the costs of prescription medications, hospital admissions, and time lost from work. Severe asthma persists in most patients, particularly in those with more comorbidities or with low socioeconomic status. Recently, the concept of targeting treatable traits has been advocated as an effective approach to managing severe asthma. The main components of management of severe asthma include providing structured education, instituting non-pharmacological interventions when appropriate, stepping-up or stepping down pharmacological treatments and adding biological therapies for patients with markers of type 2 inflammation. Bronchial thermoplasty is an additional treatment option for severe refractory asthma.

Bronchial thermoplasty is a non-pharmacological intervention that applies thermal energy to the airways with the aim of reducing the amount of airway smooth muscle and improving asthma control. Previously published articles provide detailed information on the preclinical and clinical development of bronchial thermoplasty. The main evidence for the efficacy and short-term safety of bronchial thermoplasty treatment in patients with moderate to severe asthma is based on the results of three randomized controlled trials, two of which compared bronchial thermoplasty with usual care, the Asthma Intervention Research (AIR) trial and the Research in Severe Asthma (RISA) trial, and a third trial (AIR2), which compared bronchial thermoplasty with a sham procedure. A Cochrane systematic review of the results of these trials concluded that bronchial thermoplasty produced a modest clinical benefit in asthma quality of life questionnaire (AQLQ) score (mean difference in AQLQ score 0.28, 95% CI 0.07 to 0.50) and based on the results of the AIR2 trial, bronchial thermoplasty was associated with a reduction in the rate of severe exacerbations in the 12 months after treatment.

A systematic review undertaken by the US Agency for Healthcare and Quality of the three randomized controlled trials with 5-year single-arm follow-up and several descriptive studies published up to April 2017 concluded that bronchial thermoplasty was modestly beneficial in some patients with asthma although the procedure is not without risks, particularly around the time of treatment. During the treatment period, defined as the time from pretreatment to 6 weeks after the last (third) treatment, bronchial thermoplasty is associated with an increase in asthma-related symptoms and a 3.5-fold (95% CI 1.26 to 9.68) greater risk of hospital admission for asthma. In the posttreatment period, defined as the time from 6 weeks after the last (third) treatment to 1 year, there was no difference in the risk of hospital admission (risk ratio 1.12 (95% CI 0.44 to 2.85)). Observational follow-up studies on the long-term safety of bronchial thermoplasty for participants to the AIR, RISA and AIR2 trials, from beyond 1 up to 5 years post bronchial thermoplasty treatment, reported stable lung function and lack of increase in hospital admissions and emergency department visits. A systemic review of the long-term safety of bronchial thermoplasty in the three controlled trials of bronchial thermoplasty and their respective extension studies demonstrated no long-term decline in FEV1, no change in the number of emergency room visits or hospital admissions for adverse respiratory events, and found a reduction in the frequency of respiratory adverse events. BT10+ (bronchial thermoplasty at 10 years follow-up or beyond) observational study assessed the safety and efficacy of the procedure in patients who previously participated in the AIR, RISA and AIR2 trials (ClinicalTrials.gov Identifier: NCT03243292). Of the 429 patients enrolled in the clinical trials, 192 had follow-up at >10 years post treatment (137 treated with bronchial thermoplasty; 18 control/sham participants treated with bronchial thermoplasty after the trial; 37 control/sham only). At the >10-year visit after bronchial thermoplasty, the preliminary findings were that AQLQ scores and severe exacerbation rates were comparable with those recorded 1 year after the procedure suggesting that the response to bronchial thermoplasty was sustained over 10 years.

The interpretation of the evidence for the efficacy and safety of bronchial thermoplasty in severe asthma provided by the published clinical trials has generated considerable controversy. The main criticism of the AIR and RISA trials is that the clinical outcomes in the bronchial thermoplasty group were compared with a control group who did not undergo a sham procedure. In the AIR2 trial, criticisms include that not all patients had severe refractory asthma, that the changes in the primary end point AQLQ were statistically significant, but the clinical relevance was questioned and that inappropriate methods were used to analyze some secondary end points. Several AIR2 trial coauthors have provided rebuttals to these criticisms. In the long-term follow-up studies of the three trials, the participants treated with bronchial thermoplasty were followed for 5 years, whereas the usual care group was not reviewed after year 1 in the RISA and AIR2 trials, and in...
the AIR trial, control participants were followed-up only to the end of year 3. The criteria used to obtain regulatory approval of medical devices, such as bronchial thermoplasty, are less stringent than that required for biologics and small-molecule drugs for asthma. Despite reservations in the strength of the evidence from clinical trials on the efficacy and safety of bronchial thermoplasty, the procedure has been approved for the treatment of severe asthma in many countries worldwide and its use is included in national and international asthma guidelines.7,27

This review summarizes recent publications on the criteria used to select patients with severe asthma for bronchial thermoplasty, progress in identifying predictors of a beneficial response and developments in the procedure and discusses specific issues about bronchial thermoplasty including effectiveness in clinical practice, mechanism of action, cost-effectiveness, and place in management.

**Patient Selection**

Patients being considered for bronchial thermoplasty should undergo systematic evaluation at a specialist asthma clinic to identify and manage causes of difficult-to-control asthma, such as non-adherence or untreated comorbidities. Bronchial thermoplasty is a treatment option for patients with severe refractory asthma that remains uncontrolled despite maximal therapy. Recent reviews provide detailed information on the selection of patients for bronchial thermoplasty.13,28-30 The main criteria used to select patients with severe asthma for bronchial thermoplasty are based on those used in the AIR2 and RISA controlled clinical trials of the procedure (Table 1). Observational studies from North America, the UK, and Australia indicate that patients treated with bronchial thermoplasty in clinical practice have more severe disease than those recruited to AIR and AIR2 trials (Table 1).16,31,32 The PAS2 (Post-Food and Drug Administration Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma) study enrolled 284 participants from 2011 at 27 centers in the USA (n=23) and Canada (n=4) of whom 279 patients received at least one bronchial thermoplasty treatment.33 PAS2 study participants compared to those recruited to the AIR2 clinical trial were slightly older, more subjects had chronic sinus disease (30.4% vs 18.4%), a larger number had severe asthma (94.7% vs 82.1%), a higher proportion were taking maintenance oral corticosteroids (18.9% vs 4.2%) and more subjects had experienced severe exacerbations (74% vs 52%) and hospitalizations (15.3% vs 4.2%) in the 12 months prior to bronchial thermoplasty. An audit of 126 patients with severe refractory asthma who underwent bronchial thermoplasty in clinical practice in the UK between 2011 and 2016 were on average older, had lower AQLQ scores and worse baseline FEV1 compared with the AIR and AIR2 trial participants, whereas FEV1 values were higher than RISA trial participants.34 A recent case series of consecutive patients with severe asthma included in the Australian Bronchial Thermoplasty Registry reported that the safety and effectiveness of bronchial thermoplasty in patients with an FEV1 less than 50% was similar to that in those with better lung function.35 Contraindications to bronchial thermoplasty include patients with a pacemaker, internal defibrillator, or other implantable electronic device, or who have previously received treatment with bronchial thermoplasty.36 An European consensus statement on bronchial thermoplasty also listed tracheal stenosis and anticoagulation (international normalized ratio >1.5) as contraindications to bronchial thermoplasty.37 The balance of risks and benefits of bronchial thermoplasty treatment should be discussed with patients being considered for the procedure.

**Predictors Of A Beneficial Response**

An important goal for the future use of bronchial thermoplasty in the management of severe asthma is to identify factors that predict a beneficial response.38 Preliminary reports suggest that early-onset atopic severe asthma,39 lower age,34 and increased cough receptor sensitivity to capsaicin40 may be predictive, although further confirmatory evidence is awaited. A history of self-reported allergy21 or bronchodilator reversibility41 is reported not to be predictive. Patients with severe asthma and an FEV1 <80% have more airway smooth muscle mass than those subjects with an FEV1 >80% and they have the greatest reduction in airway smooth muscle mass at 6 months after bronchial thermoplasty.42 In one study, the amount of airway smooth muscle at baseline did not predict a beneficial clinical response to bronchial thermoplasty.43 A study of 24 patients with severe asthma undergoing bronchial thermoplasty found that the number of activations delivered to the airways was higher in responders compared to non-responders to bronchial thermoplasty (221 ± 45 activations versus 139 ± 11 activations, respectively) and that the improvement in asthma control questionnaire score correlated with a greater number of activations.44 A recent study used human lung specimens and mathematical modeling guided by structural or functional patient data to predict clinical outcomes after bronchial thermoplasty.
<table>
<thead>
<tr>
<th>Criteria</th>
<th>Key Inclusion And Exclusion Criteria For Bronchial Thermoplasty Used In AIR2&lt;sup&gt;16&lt;/sup&gt; And RISA Trials&lt;sup&gt;15a&lt;/sup&gt;</th>
<th>Eligibility Criteria For Bronchial Thermoplasty Used In Clinical Practice From Selected Case Reports And Case Series</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Inclusion criteria: Adult; age 18-65 years.</td>
<td>Adult; age &gt;65 years&lt;sup&gt;53,60,63&lt;/sup&gt;</td>
</tr>
<tr>
<td>Current treatment</td>
<td>Inclusion criteria: Asthma requiring regular maintenance medications that includes inhaled corticosteroids (&gt;1000 μg beclometasone per day or equivalent (AIR2 trial); &gt;750 μg fluticasone propionate per day or equivalent (RISA trial)); and long-acting β&lt;sub&gt;2&lt;/sub&gt;-agonist (≥100 μg salmeterol per day or equivalent), with or without other asthma medications. Oral corticosteroids at a dosage ≤10 mg per day (AIR2 trial) or ≤30 mg per day (RISA trial).</td>
<td>Oral corticosteroids at a dosage &gt;10 mg per day&lt;sup&gt;32,42,57,63,71&lt;/sup&gt;</td>
</tr>
<tr>
<td>Asthma Quality of Life Questionnaire (AQLQ) score</td>
<td>Inclusion criteria: Baseline AQLQ score 6.25 or lower.</td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td>Exclusion criteria: chronic sinus disease (AIR2 trial), uncontrolled sinus disease (RISA trial); anticoagulants; use of immunosuppressants other than corticosteroids</td>
<td>Chronic sinus disease (PAS2 study)&lt;sup&gt;33&lt;/sup&gt;</td>
</tr>
<tr>
<td>Smoking status</td>
<td>Inclusion criteria: Nonsmoker for 1 year or greater with a less than 10 pack-years smoking history.</td>
<td>Former smokers &gt;10 pack-years total smoking history&lt;sup&gt;54&lt;/sup&gt; or Current smoker, n=16&lt;sup&gt;60&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lung function</td>
<td>Inclusion criteria: pre-bronchodilator FEV&lt;sub&gt;1&lt;/sub&gt; ≥60% predicted (AIR2); FEV&lt;sub&gt;1&lt;/sub&gt; ≥50% predicted (RISA trial); Exclusion criteria: post-bronchodilator FEV&lt;sub&gt;1&lt;/sub&gt; &lt;55% predicted (RISA trial); diffusing capacity (DLCO) &lt;70% predicted (RISA trial)</td>
<td>Prebronchodilator FEV&lt;sub&gt;1&lt;/sub&gt; &lt;60% predicted&lt;sup&gt;11,33,53,58,60,63,110&lt;/sup&gt;</td>
</tr>
<tr>
<td>None of the following within the past 12 months</td>
<td>Exclusion criteria i. Three or more lower respiratory tract infections (AIR2 trial); in the last 3 months (RISA trial) ii. Four or more oral corticosteroid pulses for asthma exacerbation iii. Three or more hospitalizations for asthma</td>
<td></td>
</tr>
<tr>
<td>None of the following within the past 24 months</td>
<td>Exclusion criteria i. History of life-threatening asthma (history of intubation for asthma or intensive care unit admission for asthma)</td>
<td>History of life-threatening asthma&lt;sup&gt;53&lt;/sup&gt;</td>
</tr>
<tr>
<td>Suitability to undergo bronchoscopy</td>
<td>Inclusion criteria</td>
<td>Patient considered suitable for bronchoscopy</td>
</tr>
</tbody>
</table>
compared with current clinical practice. One session of structure-guided treatment produced improvements comparable with three sessions of unguided treatment, whereas function-guided treatment provided no additional benefit compared with current practice. Studies underway may provide insights into novel clinical or inflammatory predictors of a therapeutic response to bronchial thermoplasty (ClinicalTrials.gov Identifier: NCT01185275). Imaging of the airways by optical coherence tomography, computed tomography (CT) and endobronchial ultrasound are also being investigated as potential noninvasive methods to identify predictors of a beneficial response to bronchial thermoplasty.

**Developments In The Procedure**

The “Alair” Bronchial Thermoplasty system produces radio-frequency energy that is repeatedly applied for a 10-s period per activation to the medium and large airways via a catheter with an expandable electrode array at its distal end. Bronchial thermoplasty is given over three bronchoscopy sessions at approximately 3-week intervals, one for each lower lobe and one for both upper lobes. Patients receive treatment over three outpatient flexible bronchoscopy sessions under conscious sedation spaced at approximately 3-week intervals, one for each lower lobe and one for both upper lobes. The right middle lobe bronchus is not normally treated, although a case series of 17 patients reported that bronchial thermoplasty treatment to the right middle lobe could be safely performed. In some centers, bronchial thermoplasty is performed under general anesthesia. Treatment sessions are typically completed in 45 mins and around 60 radio-frequency activations delivered to the airways. Details of the equipment and procedure have been reviewed in detail previously.

Hyperpolarized xenon (HXe) MRI is being investigated as a biomarker to prioritize the order of airway treatment by bronchial thermoplasty (ClinicalTrials.gov Identifier: NCT01832363; NCT02263794). A pilot study reported that one bronchial thermoplasty treatment guided by HXeMRI to select the six most involved airways resulted in improvements in AQLQ score at 3 months with fewer adverse effects (n=15 participants) compared to three treatments with bronchial thermoplasty (n=14 participants). An observational study reported that the use of a thinner bronchoscope (outer diameter of 4.2 mm at the distal end) facilitated access to the bronchial tree that resulted in increased radio-frequency treatment delivered during a bronchial thermoplasty session. An European consensus statement recommended that patients treated with bronchial thermoplasty should remain under long-term follow-up at the treating center.

**Effectiveness Of Bronchial Thermoplasty Under Real-World Conditions**

In the last 6 years, observational studies from Australia, Brazil, Canada, Denmark, France, Ireland, Japan, Korea, Netherlands, Spain, the UK and the USA have reported on the effectiveness of bronchial thermoplasty. Other observational studies in real-life patients have reported improvement in AQLQ scores, reductions in exacerbations and/or a step-down in treatment in 50–75% of patients undergoing bronchial thermoplasty. The United Kingdom Severe Asthma Registry of 86 patients undergoing bronchial thermoplasty reported clinical significant improvements in AQLQ at 12 months of follow-up and reductions in hospital admissions at 24 months. Other observational studies in real-life patients have reported improvement in AQLQ scores, reductions in exacerbations and/or a step-down in treatment in 50–75% of patients undergoing bronchial thermoplasty. The Bronchial Thermoplasty Global Registry of 159 patients enrolled at 19 centers in eight countries reported improvements in clinical outcomes, health-care utilization, and medication use at 1 year after bronchial thermoplasty. Respiratory-related serious adverse effects during the treatment phase with bronchial thermoplasty (first bronchial thermoplasty treatment to 6 weeks after last procedure) were
more frequent in the PAS2 study compared to AIR2: severe exacerbations, 55.8% versus 40.5%, respectively; emergency room visits, 15.8% versus 5.3%, respectively. Emergency respiratory hospital readmission rates within 30 days of bronchial thermoplasty were similar: 13.2% versus 8.4%, respectively. In observational studies, hospital admission rates during the treatment phase ranged from 10% to 30%. The United Kingdom Severe Asthma Registry recorded a hospital admission rate of 11.8% in 59 cases undergoing bronchial thermoplasty. The reduction in FEV1 after bronchial thermoplasty is transient, occur more often after upper lobe treatment and is associated to the number of radio-frequency activations. Acute CT pulmonary peribronchial consolidation frequently occurs shortly after bronchial thermoplasty, but resolves in most patients within 1–6 months. Case report describes adverse effects associated with bronchial thermoplasty including mild central bronchiectasis developing 1 month after treatment, bilateral upper lobe atelectasis associated with the development of a pulmonary cyst and pneumothorax on day 6 after a third procedure, atelectasis due to fibrin plug formation within hours of treatment, and haemoptysis associated with bronchial nodules showing areas of hemorrhagic necrosis following a second procedure, which resolved by the third session of bronchial thermoplasty.

Observational studies provide a low-grade of evidence on the effectiveness of bronchial thermoplasty due to weakness in study design, such as lack of data on clinical outcomes of a control group not treated with bronchial thermoplasty and small sample size. The PAS2 study excluded the most severe patients seen in clinical practice, such as those with a baseline FEV1 <60%, more than three hospitalizations, four or more courses of systemic corticosteroids in the last 12 months and oral corticosteroid maintenance dose >10 mg daily. Nevertheless, these studies suggest that bronchial thermoplasty is effective in one half to three-quarters of “real-life” patients with severe asthma and that it can be safely performed in clinical practice although peri-procedure adverse effects occur more often than in clinical trials.

**Mechanism Of Action Of Bronchial Thermoplasty**

Postulated mechanisms of action of bronchial thermoplasty include alterations in the structure and/or function of airway smooth muscle, epithelial cells, nerves, glands, extracellular matrix components, and/or inflammatory cells. Improvements in small airway function and/or a placebo effect from the procedure could also contribute to better clinical outcomes. The evidence supporting each of these pathways is summarized below, although to date, the precise mode of action of bronchial thermoplasty in asthma is uncertain.

**Airway Smooth Muscle**

Airway remodeling in severe asthma includes an increase in airway smooth muscle mass, which is associated with impaired lung function, airway hyperresponsiveness, and poor symptom control. Airway smooth muscle remodeling can occur in the absence of inflammation and thus it might not be responsive to anti-inflammatory therapies. Bronchial thermoplasty reduces the amount of airway smooth muscle in experimental animals, in patients with bronchial carcinoma awaiting lung resection and in patients with asthma. Evidence is conflicting to whether reduced airway smooth muscle mass is associated with improvements in clinical outcomes after bronchial thermoplasty. A preliminary report of pre- and post-bronchial thermoplasty data pooled for 99 patients at seven centers reported that airway smooth muscle mass and reticular basement thickness were reduced by bronchial thermoplasty beyond 1 year, but that these improvements in airway remodeling were not associated to improved clinical outcomes. A small study in 10 patients with severe asthma reported that CT airway volume increased 4 weeks after bronchial thermoplasty on the treated side compared to untreated airways. The improvement in CT airway volume was associated with a nonsignificant trend for an improvement in symptoms indicating the need for a larger study to confirm these preliminary findings. Other imaging studies performed up to 2 years after bronchial thermoplasty reported CT airway wall thickness was reduced and optical coherence tomographic airway wall thickness was decreased in a patient who responded to the procedure and increased in a nonresponder. A study involving the in vitro and in silico modeling of the acute effects of bronchial thermoplasty on airway smooth muscle cells concluded that the extent of the reduction in airway smooth muscle mass after bronchial thermoplasty was insufficient to explain the clinical benefits. Bronchial thermoplasty has been postulated to target airway smooth muscle function by additional mechanisms to the reduction in airway smooth muscle mass, including decreased contractility of airway smooth muscle by directly disrupting actin–myosin interactions, by stiffening the airway wall.
or by reducing the secretion of pro-inflammatory mediators from airway smooth muscle cells.\(^77\)

**Airway Epithelium**

A bronchial biopsy study of 33 patients with severe asthma found increased bronchial epithelial cell proliferation at 3 weeks after bronchial thermoplasty that returned to baseline levels at \(\geq 12\) months.\(^89\) The ASMA\(\text{THERM}\) (Bicentric Prospective Study, Evaluating Bronchial THERMOPLASTY in Patients Presenting Severe Uncontrolled Asthma) study found no alteration to the histology of the bronchial epithelium at 3 months after the procedure.\(^43\) Based on the results of an in vivo study showing increased epithelial integrity after bronchial thermoplasty and in vitro and in silico modeling of the acute effects of bronchial thermoplasty on airway epithelial and smooth muscle cells, Chernyavsky et al\(^87\) postulated that epithelial repair might contribute to the clinical benefits of bronchial thermoplasty. Using bronchoalveolar lavage (BAL) and bronchial epithelial biopsies obtained from patients with asthma both before and up to 12 weeks after bronchial thermoplasty, Sun et al\(^90\) reported that BAL fluid and epithelial cell culture supernatant decreased mitochondrial mass and fibroblast proliferation by blocking epithelium-derived heat shock protein 60 (HSP60) secretion and protein arginine methyltransferase 1 (PRMT1) expression in fibroblasts. Based on these findings, the authors hypothesized that bronchial thermoplasty decreases fibroblast remodeling by reducing the function of airway epithelial cells.\(^90\)

**Airway Glands**

The ASMA\(\text{THERM}\) study found no alteration in subepithelial mucous glands or goblet cell hypertrophy or hyperplasia at 1 year after bronchial thermoplasty.\(^43\) A recent study reported a decrease in bronchial epithelial Mucin 5AC (MUC5AC) expression after bronchial thermoplasty that correlated with a decrease in expression of interleukin (IL)13.\(^89\) The authors speculated that as IL13 is a potent inducer of mucus secretion and goblet cell hyperplasia, bronchial thermoplasty-induced reduction in IL13 may contribute to a decrease in MUC5AC and improvements in clinical outcomes after the procedure.\(^89\)

**Airway Nerves**

Several studies have reported an alteration to airway nerves after bronchial thermoplasty,\(^43,83,91\) including reduced nerve fibers in the submucosa\(^91\) and airway smooth muscle\(^43,91\) and a decrease in epithelial neuroendocrine cells.\(^43\) In one study, the number of epithelial neuroendocrine cells correlated with the number of severe exacerbations and asthma control test and AQLQ scores at 1 year after bronchial thermoplasty.\(^43\) Facciolo\(\text{g}o\) et al\(^91\) postulated that the reduction in nerve fibers in the submucosa and airway smooth muscle may attenuate nerve reflexes and contribute to the improvement in clinical outcomes after bronchial thermoplasty.

**Airway Extracellular Matrix Components And Airway Vasculature**

Bronchial thermoplasty reduces subepithelial basement membrane thickening and type I collagen deposition.\(^43,54,55,84\) Airway vasculature is reported not to alter after bronchial thermoplasty.\(^43,83\)

**Airway Inflammation**

Preliminary studies suggest that bronchial thermoplasty can alter markers of inflammation in asthma. For example, BAL concentrations of TGF-\(\beta 1\) and chemokine (C-C motif) ligand 5 (CCL5) decreased at 6 weeks after bronchial thermoplasty, whereas BAL IL4, IL5, and IL17 concentrations\(^82\) and bronchial epithelial expression of TGF- \(\beta 1\) and IL17 were unaltered.\(^83\) An observational study reported reductions in peripheral blood eosinophils at 1 year after bronchial thermoplasty,\(^92\) although the fall in blood eosinophil count is unlikely to be due to bronchial thermoplasty, since bronchial mucosal eosinophils are not reduced by the procedure.\(^43\) Transcriptomic profiling of airway epithelial cells obtained from untreated airways after bronchial thermoplasty found alterations to several gene networks associated with neurophysiological processes linked to asthma.\(^93\)

**Small Airway Function**

Severe asthma is associated with small airway dysfunction that may contribute to worse clinical outcomes.\(^94\) Whether bronchial thermoplasty treatment to the central airways (<3 mm) can influence the structure or function of the peripheral airways in severe asthma is unclear.\(^95,96\) CT image evidence of acute peribronchial consolidations adjacent to airways treated with bronchial thermoplasty is likely to involve the peripheral airways, although it is not known whether this induces long-term structural changes to these airways.\(^67,68\) Several small observational studies of the effects of bronchial thermoplasty on lung function and imaging of small airway function in severe asthma have produced conflicting results.\(^48,97,98\) In a group of 32 patients...
with severe asthma, residual volumes (RVs) decreased by 7% at 6 months after bronchial thermoplasty. In a subgroup with baseline FEV₁ of <60% predicted, gas trapping (RV/TLC ratio) was slightly reduced, a finding which suggests an effect of bronchial thermoplasty on the small airways. In contrast to these findings, a study of 43 patients with severe asthma from the same Australian centers found that forced oscillometry, at test used to assess small airway function was unaltered after bronchial thermoplasty. Another study in patients with severe asthma using imaging helium 3 MRI and CT imaging demonstrated improved ventilation defects after bronchial thermoplasty.

**Placebo Effect**

Patients with uncontrolled asthma can derive considerable clinical benefits from randomization to placebo. The sham-controlled arm of the AIR2 trial was associated with increased AQLQ scores suggesting that some of the improvement in clinical outcomes clinical from bronchial thermoplasty may be due to a placebo effect. Nevertheless, in the AIR2 trial, a larger proportion of bronchial thermoplasty subjects than sham group subjects experienced a clinically meaningful within-subject improvement in AQLQ score of 0.5 or greater.

**Cost-Effectiveness**

Bronchial thermoplasty treatment of severe asthma is more cost-effective in health-care systems where the costs of hospitalization and emergency department are low and the costs of the procedure are low. For example, in the USA, bronchial thermoplasty is estimated to be cost-effective in patients with severe uncontrolled asthma who have a high risk of exacerbations or who have severe allergic asthma, whereas in Singapore, the procedure is not cost-effective compared to optimized usual care. The threshold for health systems willingness-to-pay per quality-adjusted life years (QALY) influences the cost-effectiveness of the procedure. An indirect comparison of bronchial thermoplasty with omalizumab in patients with moderate-to-severe allergic asthma in the USA reported greater than a 60% chance that bronchial thermoplasty was cost-effective relative to omalizumab and standard therapy at the willingness-to-pay of $100,000 per QALY.

**Place In Management Of Bronchial Thermoplasty In Severe Asthma**

The Global Initiative for Asthma (GINA) report provides recommendations on the investigation and management of adults and adolescents with difficult-to-treat asthma. The initial components include 1) confirmation of the diagnosis; 2) identification of factors contributing to poorly controlled asthma, such as poor inhaler technique, suboptimal adherence, modifiable risk factors and comorbidities; and 3) optimizing management by addressing aggravating contributory factors, considering add-on small-molecule drug therapies and non-pharmacological interventions, and/or considering a trial of high-dose ICS. After 3 to 6 months observation, patients with persistent uncontrolled asthma are assessed whether the diagnosis is severe refractory asthma. The inflammatory phenotype of severe asthma should be determined to identify those individuals with type 2 inflammation, who should be considered for add-on type 2 biologic therapies, such as anti-IgE, anti-IL5/anti-IL5R, or anti-IL4R. Patients with non-type 2 inflammation should be considered for add-on therapies, such as macrolides or low dose oral corticosteroids. GINA considers bronchial thermoplasty as an additional treatment option for patients with non-type 2 inflammation and for individuals who do not obtain a good response to type 2 targeted therapies. Overall, GINA considers that bronchial thermoplasty is a potential treatment option (Evidence grade B) at Step 5 in some countries for selected adults with severe asthma whose asthma remains uncontrolled despite optimized therapy and review by an asthma specialist. Longer-term safety follow-up of larger number of active and control patients is required to assess effectiveness and safety. Both GINA and the International ERS/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma recommend that bronchial thermoplasty is undertaken in adults with severe asthma only in the context of an Institutional Review Board approved independent systematic registry or a clinical study. The British guideline
on the management of asthma states that bronchial thermoplasty can be considered for the treatment of adult patients (aged 18 and over) with severe asthma who have poorly controlled asthma despite optimal medical therapy (Grade B recommendation). The guideline recommends that potential candidates for bronchial thermoplasty should have the diagnosis of uncontrolled symptoms due to severe asthma confirmed and that they are considered to be adherent with current therapies. Patients should be assessed by an asthma specialist with expertise in bronchial thermoplasty and treated at a center with appropriate resources. Details of all patients undergoing bronchial thermoplasty should be entered in the United Kingdom Severe Asthma Registry.

Some specialists in bronchial thermoplasty recommend that the procedure should be considered for patients with severe asthma associated with non-type 2 inflammation or as an alternative therapy for patient unresponsive to currently licensed type 2 therapies. A European Consensus statement on bronchial thermoplasty developed by a panel of five European experts could not agree whether bronchial thermoplasty should be considered before or only after trials of type 2 targeted therapies. There are no clinical studies that have directly compared the effectiveness of bronchial thermoplasty with biological type 2 targeted agents. An indirect comparison of clinical outcomes, including severe exacerbations, emergency department visits, and hospital admissions in the AIR2 trial, were reported to be broadly similar to those in two placebo-controlled trials of omalizumab (INNOVATE and EXTRA). Severe exacerbations were less for omalizumab compared to the total duration of the AIR2 study that included the increase in exacerbations during the peri-treatment period.

The place of bronchial thermoplasty in the treatment of severe asthma remains to be clearly defined. The author's suggestion for the use of bronchial thermoplasty and biologics in management of severe asthma in clinical practice is outlined in Figure 1. Future studies need to assess the effectiveness of bronchial thermoplasty targeted to remodeled airways, compared with biologic therapies or in combination with biologics, and in different inflammatory phenotypes. The high costs and difficulties undertaking comparative clinical studies using treatments developed by different

---

**Figure 1** Algorithm to guide the selection of patients with severe refractory asthma for treatment with biologics and bronchial thermoplasty.

**Note:** Biologics and bronchial thermoplasty are treatment options for patients with severe asthma (Step 5) who have uncontrolled asthma despite high-dose ICS plus long-acting β2-agonist and the long-acting muscarinic antagonist tiotropium and after assessment and management of causes of difficult-to-control asthma, such as nonadherence, poor inhaler technique, comorbidities, under treatment, and other behavioral factors.
pharmaceutical and device companies might prevent new large clinical trials being undertaken. New data on the effectiveness of bronchial thermoplasty and the identification of predictors of response are likely to come from observational studies in real-world populations of severe asthma.

Conclusions
Bronchial thermoplasty is approved in many countries worldwide as a non-pharmacological treatment for severe asthma based on the results of a small number of controlled clinical trials. Bronchial thermoplasty modestly improves clinical outcome in severe asthma including asthma quality of life and risk of exacerbations. Asthma morbidity increases during and shortly after treatment. Longer follow-up studies provide reassurance on long-term safety. In clinical practice, patients treated with bronchial thermoplasty have worse baseline characteristics and comparable clinical outcomes compared to trial data. Uncertainties remain about predictors of response, mechanism of action, and place in management of asthma. In the future, greater understanding of the sub-phenotypes of severe asthma and mode of action of bronchial thermoplasty should allow a precision medicine approach to the use of bronchial thermoplasty in the management of severe asthma.

Disclosure
The author reports no conflicts of interest in this work.

References


